


M. Yu

Re-run

File copy

BIOTECHNOLOGY  
SYSTEMS  
BRANCH



**RAW SEQUENCE LISTING**  
**ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/851,422  
Source: 600  
Date Processed by STIC: 7/2/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: [patin3help@uspto.gov](mailto:patin3help@uspto.gov) or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER  
VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND  
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002



RECEIVED

JUL 08 2002

TECH CENTER 1600/2900



RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/851,422

DATE: 07/02/2002  
TIME: 14:19:58

Input Set : A:\35879122.app  
Output Set: N:\CRF3\07022002\I851422.raw

1600  
#12  
JW  
7/13/02  
Does Not Comply  
Corrected Diskette Needed

3 <110> APPLICANT: YU, XIANXHANG  
4 WAGNER, THOMAS E.  
6 <120> TITLE OF INVENTION: THERAPEUTIC PORE-FORMING PEPTIDES  
8 <130> FILE REFERENCE: 035879/0122  
10 <140> CURRENT APPLICATION NUMBER: 09/851,422  
11 <141> CURRENT FILING DATE: 2001-05-09  
13 <150> PRIOR APPLICATION NUMBER: 60/203,063  
14 <151> PRIOR FILING DATE: 2000-05-09  
16 <150> PRIOR APPLICATION NUMBER: 60/212,042  
17 <151> PRIOR FILING DATE: 2000-06-16  
19 <160> NUMBER OF SEQ ID NOS: 12  
21 <170> SOFTWARE: PatentIn Ver. 2.1  
23 <210> SEQ ID NO: 1  
24 <211> LENGTH: 37  
25 <212> TYPE: PRT  
26 <213> ORGANISM: Artificial Sequence  
28 <220> FEATURE:  
29 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
30 peptide  
32 <220> FEATURE:  
33 <221> NAME/KEY: MOD\_RES  
34 <222> LOCATION: (10)..(13)  
35 <223> OTHER INFORMATION: This region may be selected from the group consisting of  
[epsilon]  
36 -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon]  
37 -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]  
38 -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.  
40 <220> FEATURE:  
41 <221> NAME/KEY: MOD\_RES  
42 <222> LOCATION: (22)..(25)  
43 <223> OTHER INFORMATION: This region may be selected from the group consisting of  
[epsilon]  
44 -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon]  
45 -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]  
46 -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.  
48 <220> FEATURE:  
49 <221> NAME/KEY: MOD\_RES  
50 <222> LOCATION: (34)..(37)  
51 <223> OTHER INFORMATION: This region may be selected from the group consisting of  
[epsilon]  
52 -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon]  
53 -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]  
54 -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.  
56 <220> FEATURE:



57 <223> OTHER INFORMATION: This molecule may encompass smaller embodiments according  
58 to the application as filed



## RAW SEQUENCE LISTING

DATE: 07/02/2002

PATENT APPLICATION: US/09/851,422

TIME: 14:19:58

Input Set : A:\35879122.app

Output Set: N:\CRF3\07022002\I851422.raw

```

60 <400> SEQUENCE: 1
W--> 61 Gly Phe Ile Ala Thr Leu Cys Thr Lys Xaa Xaa Xaa Xaa Val Leu Asp
      62   1             5             10             15
W 64 Phe Gly Ile Asp Lys Xaa Xaa Xaa Xaa Leu Ile Gln Leu Ile Glu Asp
      65             20             25             30
W--> 67 Lys Xaa Xaa Xaa Xaa
      68             35
71 <210> SEQ ID NO: 2
72 <211> LENGTH: 38
73 <212> TYPE: PRT
74 <213> ORGANISM: Artificial Sequence
76 <220> FEATURE:
77 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
78     peptide
80 <220> FEATURE:
81 <221> NAME/KEY: MOD_RES
82 <222> LOCATION: (8)..(11)
83 <223> OTHER INFORMATION: This region may be selected from the group consisting of
[epsilon
84     -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
85     -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
86     -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
88 <220> FEATURE:
89 <221> NAME/KEY: MOD_RES
90 <222> LOCATION: (26)..(29)
91 <223> OTHER INFORMATION: This region may be selected from the group consisting of
[epsilon
92     -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
93     -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
94     -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
96 <220> FEATURE:
97 <221> NAME/KEY: MOD_RES
98 <222> LOCATION: (32)..(35)
99 <223> OTHER INFORMATION: This region may be selected from the group consisting of
[epsilon
100     -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
101     -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
102     -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
104 <220> FEATURE:
105 <223> OTHER INFORMATION: This molecule may encompass smaller embodiments according
106     to the application as filed
108 <400> SEQUENCE: 2
W--> 109 Gly Ile Gly Ala Val Leu Lys Xaa Xaa Xaa Xaa Val Leu Thr Thr Gly
      110   1             5             10             15
W 112 Leu Pro Ala Leu Ile Ser Trp Ile Lys Xaa Xaa Xaa Xaa Arg Lys Xaa
      113             20             25             30
W--> 115 Xaa Xaa Xaa Arg Gln Gln
      116             35
119 <210> SEQ ID NO: 3
120 <211> LENGTH: 25
121 <212> TYPE: PRT
122 <213> ORGANISM: Entamoeba histolytica

```



## RAW SEQUENCE LISTING

DATE: 07/02/2002

PATENT APPLICATION: US/09/851,422

TIME: 14:19:58

Input Set : A:\35879122.app

Output Set: N:\CRF3\07022002\I851422.raw

```

124 <400> SEQUENCE: 3
125 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
126   1           5           10           15
128 Lys Leu Ile Gln Leu Ile Glu Asp Lys
129           20           25
132 <210> SEQ ID NO: 4
133 <211> LENGTH: 37
134 <212> TYPE: PRT
135 <213> ORGANISM: Antheraea pernyi
137 <220> FEATURE:
138 <223> OTHER INFORMATION: Cecropin A
140 <400> SEQUENCE: 4
141 Lys Trp Lys Leu Phe Lys Lys Ile Glu Lys Val Gly Gln Asn Ile Arg
142   1           5           10           15
144 Asp Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Val Gly Gln Ala
145           20           25           30
147 Thr Gln Ile Ala Lys
148           35
151 <210> SEQ ID NO: 5
152 <211> LENGTH: 35
153 <212> TYPE: PRT
154 <213> ORGANISM: Antheraea pernyi
156 <220> FEATURE:
157 <223> OTHER INFORMATION: Cecropin B
160 <400> SEQUENCE: 5
161 Lys Trp Lys Ile Phe Lys Lys Ile Glu Lys Val Gly Arg Asn Ile Arg
162   1           5           10           15
164 Asn Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Leu Gly Glu Ala
165           20           25           30
167 Lys Ala Leu
168           35
171 <210> SEQ ID NO: 6
172 <211> LENGTH: 36
173 <212> TYPE: PRT
174 <213> ORGANISM: Antheraea pernyi
176 <220> FEATURE:
177 <223> OTHER INFORMATION: Cecropin D
179 <400> SEQUENCE: 6
180 Trp Asn Pro Phe Lys Glu Leu Glu Lys Val Gly Gln Arg Val Arg Asp
181   1           5           10           15
183 Ala Val Ile Ser Ala Gly Pro Ala Val Ala Thr Val Ala Gln Ala Thr
184           20           25           30
186 Ala Leu Ala Lys
187           35
190 <210> SEQ ID NO: 7
191 <211> LENGTH: 26
192 <212> TYPE: PRT
193 <213> ORGANISM: Apis mellifera
195 <400> SEQUENCE: 7

```



## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/851,422

DATE: 07/02/2002

TIME: 14:19:58

Input Set : A:\35879122.app

Output Set: N:\CRF3\07022002\I851422.raw

```

196 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
197   1           5           10           15
199 Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
200           20           25
203 <210> SEQ ID NO: 8
204 <211> LENGTH: 27
205 <212> TYPE: PRT
206 <213> ORGANISM: Artificial Sequence
208 <220> FEATURE:
209 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
210 peptide
212 <220> FEATURE:
213 <221> NAME/KEY: MOD_RES
214 <222> LOCATION: (26)..(27)
215 <223> OTHER INFORMATION: [epsilon-gamma]-Glu-[alpha-gamma]-Glu
217 <400> SEQUENCE: 8
218 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
219   1           5           10           15
W-221 Lys Leu Ile Gln Leu Ile Glu Asp Lys Xaa Xaa
222           20           25
225 <210> SEQ ID NO: 9
226 <211> LENGTH: 26
227 <212> TYPE: PRT
228 <213> ORGANISM: Artificial Sequence
230 <220> FEATURE:
231 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
232 peptide
234 <220> FEATURE:
235 <221> NAME/KEY: MOD_RES
236 <222> LOCATION: (26)
237 <223> OTHER INFORMATION: [epsilon-alpha]-Phe
239 <400> SEQUENCE: 9
240 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
241   1           5           10           15
W-243 Lys Leu Ile Gln Leu Ile Glu Asp Lys Xaa
244           20           25
247 <210> SEQ ID NO: 10
248 <211> LENGTH: 27
249 <212> TYPE: PRT
250 <213> ORGANISM: Artificial Sequence
252 <220> FEATURE:
253 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
254 peptide
256 <220> FEATURE:
257 <221> NAME/KEY: MOD_RES
258 <222> LOCATION: (18)
259 <223> OTHER INFORMATION: [epsilon-alpha]-Phe
261 <220> FEATURE:
262 <221> NAME/KEY: MOD_RES

```



## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/851,422

DATE: 07/02/2002

TIME: 14:19:58

Input Set : A:\35879122.app

Output Set: N:\CRF3\07022002\I851422.raw

263 <222> LOCATION: (27)  
 264 <223> OTHER INFORMATION: [epsilon-alpha]-Phe  
 266 <400> SEQUENCE: 10  
 267 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp  
 268 1 5 10 15  
 W--> 270 Lys Xaa Leu Ile Gln Leu Ile Glu Asp Lys Xaa  
 271 20 25  
 274 <210> SEQ ID NO: 11  
 275 <211> LENGTH: 28  
 276 <212> TYPE: PRT  
 277 <213> ORGANISM: Artificial Sequence  
 279 <220> FEATURE:  
 280 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
 281 peptide  
 283 <220> FEATURE:  
 284 <221> NAME/KEY: MOD\_RES  
 285 <222> LOCATION: (22)  
 286 <223> OTHER INFORMATION: [epsilon-gamma]-Glu  
 288 <220> FEATURE:  
 289 <221> NAME/KEY: MOD\_RES  
 290 <222> LOCATION: (25)  
 291 <223> OTHER INFORMATION: [epsilon-gamma]-Glu  
 293 <400> SEQUENCE: 11  
 294 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu  
 295 1 5 10 15  
 O--> 297 Ile Ser Trp Ile Lys Xaa Arg Lys Xaa Arg Gln Gln  
 298 20 25  
 301 <210> SEQ ID NO: 12  
 302 <211> LENGTH: 30  
 303 <212> TYPE: PRT  
 304 <213> ORGANISM: Artificial Sequence  
 306 <220> FEATURE:  
 307 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
 308 peptide  
 310 <220> FEATURE:  
 311 <221> NAME/KEY: MOD\_RES  
 312 <222> LOCATION: (19)..(20)  
 313 <223> OTHER INFORMATION: [epsilon-gamma]-Glu-[alpha-gamma]-Glu  
 315 <220> FEATURE:  
 316 <221> NAME/KEY: MOD\_RES  
 317 <222> LOCATION: (23)..(24)  
 318 <223> OTHER INFORMATION: [epsilon-gamma]-Glu-[alpha-gamma]-Glu  
 320 <400> SEQUENCE: 12  
 321 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu  
 322 1 5 10 15  
 W--> 324 Ile Ser Trp Ile Lys Xaa Xaa Arg Lys Xaa Xaa Arg Gln Gln  
 325 20 25 30

"Trp" is at location 19 and "Ile" is at location 20

what about Xaa at location 22?

Arg is at location 24

what about Xaa's at location 26 and 27?



RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/09/851,422

DATE: 07/02/2002  
TIME: 14:19:59

Input Set : A:\35879122.app  
Output Set: N:\CRF3\07022002\I851422.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 10,11,12,13,22,23,24,25,34,35,36,37  
Seq#:2; Xaa Pos. 8,9,10,11,26,27,28,29,32,33,34,35  
Seq#:8; Xaa Pos. 26,27  
Seq#:9; Xaa Pos. 26  
Seq#:10; Xaa Pos. 18,27  
Seq#:11; Xaa Pos. 22,25  
Seq#:12; Xaa Pos. 22,23,26,27